[PRESS RELEASE] – SMITHS FALLS, Ontario, Sept. 22, 2026 – Canopy Growth Corp., a leading global company committed to bettering lives through cannabis, announced that it will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom, expanding the reach of its international cannabis business into another European market.
The Canadian-grown flower strains will be supplied to GROW Group U.K. Ltd., a manufacturer and distributor of prescribed cannabis-based medicines across Europe, which will commercialize the products in the U.K. under Canopy Growth’s global Spectrum Therapeutics medical brand. This initial launch represents the introduction of Canopy Growth’s portfolio products into the U.K. market.
“Expanding availability of our products into the U.K. is another step in growing our European medical cannabis business and broadening the international reach of our Canadian-grown flower,” Canopy Growth CEO Luc Mongeau said. “With an established EU GMP supply capability and growing demand across European medical markets, we see continued opportunity to build this part of our business through disciplined expansion into attractive markets.”
The U.K. supply builds on the recent renewal of the European Union Good Manufacturing Practice (EU GMP) certification at Canopy Growth’s Kincardine, Ontario, cultivation facility, which supports the company’s ability to serve medical cannabis markets across Europe.
